COX6C is synthesized via recombinant DNA technology, primarily in E. coli or yeast systems. Key production parameters include:
Recombinant COX6C is typically partial-length (aa 2–76) and may include affinity tags (e.g., GST, His) depending on the production protocol .
COX6C’s dysregulation is implicated in mitochondrial dysfunction and cancer progression:
COX6C is essential for:
Oxidative phosphorylation: Maintains mitochondrial membrane potential (MMP) and electron transport chain efficiency.
Mitochondrial fusion: Deficiency disrupts fusion, impairing ATP production .
COX6C amplification and overexpression are observed in multiple cancers:
Knockdown studies in lung adenocarcinoma cells (e.g., H1299) show COX6C depletion induces S-G2/M arrest, polyploidy, and apoptosis via ROS-AMPK signaling .
Recombinant COX6C is utilized in:
ELISA kits: For quantifying COX6C levels in biological samples (e.g., CSB-CF611310LBU) .
Structural studies: GST-tagged or His-tagged variants for crystallization or binding assays .
Suppliers include CUSABIO and Creative BioMart, offering products in lyophilized or liquid forms with ≥0.1 mg/mL concentrations .
COX6C’s amplification and overexpression in cancers highlight its utility as: